Trails Edge Capital Partners, LP
CIK 0002077247 · ATLANTA, GA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$629.9M
2026 Q2
Positions
35
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
50.3%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
LBRX
LB PHARMACEUTICALS INC
7.8%
NRIX
NURIX THERAPEUTICS INC
6.1%
IMCR
IMMUNOCORE HLDGS PLC
5.4%
TRAX
FIRST TRACKS BIOTHERAPEUTICS
4.8%
FDMT
4D MOLECULAR THERAPEUTICS IN
4.7%
BMRN
BIOMARIN PHARMACEUTICAL INC
4.7%
DSGN
DESIGN THERAPEUTICS INC
4.6%
XENE
XENON PHARMACEUTICALS INC
4.2%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.